Literature DB >> 24395387

Treatment of cholesterol in the elderly: statins and beyond.

John C LaRosa1.   

Abstract

Lowering of low-density lipoprotein cholesterol levels is a worthwhile intervention in older (more than 65-70 years of age) subjects, since age itself is a powerful predictor of vascular disease risk. Although studies have not consistently demonstrated an overall beneficial effect on total mortality, cardiovascular morbidity and mortality are favorably affected. The drugs most extensively studied are statins, but similar results are at least suggested for other agents. The efficacy, safety, and benefits of statins make them the drugs of choice. Statin intolerance can be managed and should not lead immediately to an abandonment of therapy. In cases in which it cannot be overcome, other lipid-lowering drugs, either singly or in combination, can be used, although their side effects are generally more problematic and their benefits are less prominent. In older patients, prevention of disability from stroke, heart disease, or peripheral vascular diseases may be as important a goal as an overall beneficial effect on mortality, which, in the long run, is unavoidable.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395387     DOI: 10.1007/s11883-013-0385-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  26 in total

Review 1.  Statins and diabetes: the good, the bad, and the unknown.

Authors:  Kelly Axsom; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  Curr Atheroscler Rep       Date:  2013-02       Impact factor: 5.113

Review 2.  Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.

Authors:  Huseyin Naci; Jasper Brugts; Tony Ades
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-07-09

3.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

4.  Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.

Authors:  Alexandra E Rätz Bravo; Lydia Tchambaz; Anita Krähenbühl-Melcher; Lorenzo Hess; Raymond G Schlienger; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

Authors:  Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski
Journal:  N Engl J Med       Date:  2013-06-24       Impact factor: 91.245

6.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

Review 7.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

Authors:  Min Jun; Celine Foote; Jicheng Lv; Bruce Neal; Anushka Patel; Stephen J Nicholls; Diederick E Grobbee; Alan Cass; John Chalmers; Vlado Perkovic
Journal:  Lancet       Date:  2010-05-10       Impact factor: 79.321

8.  Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.

Authors:  Michael H Davidson
Journal:  J Clin Lipidol       Date:  2013-03-26       Impact factor: 4.766

9.  Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.

Authors:  Peter P Toth
Journal:  J Clin Lipidol       Date:  2013-03-27       Impact factor: 4.766

Review 10.  Ezetimibe therapy: mechanism of action and clinical update.

Authors:  Binh An P Phan; Thomas D Dayspring; Peter P Toth
Journal:  Vasc Health Risk Manag       Date:  2012-07-03
View more
  3 in total

1.  Risk factors: Diabetes, fractures and mortality--statin therapy.

Authors:  Jane A Cauley
Journal:  Nat Rev Endocrinol       Date:  2015-06-02       Impact factor: 43.330

2.  Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study.

Authors:  Kristin K Clemens; Salimah Z Shariff; Eric McArthur; Robert A Hegele
Journal:  Lipids Health Dis       Date:  2018-01-08       Impact factor: 3.876

3.  The Use of Primary Care Electronic Health Records for Research: Lipid Medications and Mortality in Elderly Patients.

Authors:  Adam J Hodgkins; Judy Mullan; Darren Mayne; Andrew Bonney
Journal:  Pharmacy (Basel)       Date:  2019-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.